Acta Neuropathol (2012) 123:465–472 6. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, Garcia-Echeverria C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblas- toma. Sci Transl Med 2:51ra70 7. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL (2011) Inte- grative genomic analysis of medulloblastoma identiﬁes a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29:1424–1430 8. Clifford S, Lusher M, Lindsey J, Langdon J, Gilbertson R, Straughton D, Ellison D (2006) Wnt/wingless pathway activation and chromosome 6 loss characterise a distinct molecular sub- group of medulloblastomas associated with a favourable prog- nosis. Cell Cycle 5:2666–2670 9. de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadravec-Zalatel L, Perera M, Corte G, Wirths O, van Sluis P, Pietsch T, Troost D, Baas F, Versteeg R, Kool M (2006) OTX1 and OTX2 expression correlates with the clinicopathologic classiﬁca- tion of medulloblastomas. J Neuropathol Exp Neurol 65:1–11 10. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H (2005) Identiﬁcation of OTX2 as a medulloblastoma oncogene whose product can be targeted by all- trans retinoic acid. Cancer Res 65:919–924 11. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ (2011) Medulloblastoma: clinico- pathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381–396 12. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC (2011) Deﬁnition of disease-risk stratiﬁcation groups in child- hood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400–1407 13. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC (2005) ß-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951–7957 14. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, Raquin MA, Bours D, Carpentier S, Barillot E, Grill J, Doz F, Puget S, Janoueix-Lerosey I, Delattre O (2009) Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic proﬁles, and clinical characteristics. J Pathol 218:86–94 15. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Mer- chant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ (2006) Risk-adapted craniospinal radiotherapy followed by high- dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long- term results from a prospective, multicentre trial. Lancet Oncol 7:813–820 16. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR (2010) A pathway-based classiﬁcation of human breast cancer. Proc Natl Acad Sci USA 107:6994–6999 17. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein 471 D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ (2010) Subtypes of medulloblastoma have distinct developmental origins. Nature 468:1095–1099 18. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomﬁeld CD, Lander ES (1999) Molecular classiﬁcation of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–537 19. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, Krush AJ, Berk T, Cohen Z, Tetu B et al (1995) The molecular basis of Turcot’s syndrome. N Engl J Med 332:839–847 20. Hatten ME, Roussel MF (2011) Development and cancer of the cerebellum. Trends Neurosci 34(3):134–142 21. Kool M, Korshunov A, Remke M, Jones D, Schlanstein M, Northcott P, Cho Y, Schouten - van Meeteren N, van Vuurden D, Clifford S, Pietsch T, von Bueren A, Rutkowski S, McCabe M, Collins P, Ba¨cklund M, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison D, Gilbertson R, Pomeroy S, Taylor M, Lichter P, Pﬁster S (2011) Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of wnt, shh, group 3, and group 4 medullo- blastomas. Acta Neuropathol (under review) 22. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R (2008) Integrated genomics identiﬁes ﬁve medullo- blastoma subtypes with distinct genetic proﬁles, pathway signatures and clinicopathological features. PLoS ONE 3:e3088 23. Korshunov A, Remke M, Kool M, Hielscher T, Northcott P, Williamson D, Pfaff E, Witt H, Jones D, Ryzhova M, Cho Y, Wittmann A, Benner A, Weiss W, von Deimling A, Scheurlen W, Kulozik A, Clifford S, Collins V, Westermann F, Taylor M, Lichter P, Pﬁster S (2011) Biological and clinical heterogeneity of MYCN-ampliﬁed medulloblastoma. Acta Neuropathol. doi: 10.1007/s00401-011-0918-8 24. Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Scho¨ttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik A, von Deimling A, Lichter P, Pﬁster S (2010) Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratiﬁcation. J Clin Oncol 28:3054–3060 25. Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A, Scheithauer B, Kleihues P (2007) The 2007 WHO classiﬁcation of tumours of the central nervous system. Acta Neuropathol 114:97–109 26. McManamy CS, Pears J, Weston CL, Hanzely Z, Ironside JW, Taylor RE, Grundy RG, Clifford SC, Ellison DW (2007) Nodule formation and desmoplasia in medulloblastomas—deﬁning the nodular/desmoplastic variant and its biological behavior. Brain Pathol 17:151–164 27. Northcott P, Hielscher T, Dubuc A, Mack S, Shih D, Remke M, Al- Halabi H, Albrecht S, Jabado N, Eberhart C, Grajkowska W, Weiss W, Clifford S, Bouffet E, Rutka J, Korshunov A, Pﬁster S, Taylor M (2011) Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 122:231–240 28. Northcott P, Korshunov A, Witt H, Hielscher T, Eberhart C, Mack S, Bouffet E, Clifford S, Hawkins C, French P, Rutka J, Pﬁster S, Taylor M (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408–1414 29. Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD (2009) The miR-17/92 polycistron is 123